Fennec Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 14, 2025
Fennec Pharmaceuticals (NASDAQ: FENC), a commercial stage specialty pharmaceutical company, has scheduled its second quarter 2025 financial results announcement for Thursday, August 14, 2025. The results will be released before U.S. markets open, followed by a management conference call and webcast at 8:30 a.m. Eastern Time.
The company will host a live webcast accessible through their website, with a replay available for thirty days following the event. Participants are advised to connect at least 15 minutes early to allow for any necessary software downloads.
Fennec Pharmaceuticals (NASDAQ: FENC), azienda farmaceutica specializzata in fase commerciale, ha programmato la pubblicazione dei risultati finanziari del secondo trimestre 2025 per gioved矛 14 agosto 2025. I risultati saranno diffusi prima dell'apertura dei mercati statunitensi e saranno seguiti da una conference call e un webcast con la direzione alle 8:30 (Eastern Time).
L'azienda trasmetter脿 il webcast in diretta sul proprio sito web e la registrazione sar脿 disponibile per trenta giorni dopo l'evento. Si raccomanda ai partecipanti di collegarsi almeno 15 minuti prima per permettere l'eventuale download del software necessario.
Fennec Pharmaceuticals (NASDAQ: FENC), compa帽铆a farmac茅utica especializada en fase comercial, ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el jueves 14 de agosto de 2025. Los resultados se publicar谩n antes de la apertura de los mercados estadounidenses y a continuaci贸n habr谩 una conferencia telef贸nica y webcast con la direcci贸n a las 8:30 a.m., hora del Este.
La empresa ofrecer谩 un webcast en directo accesible desde su sitio web, y la repetici贸n estar谩 disponible durante treinta d铆as tras el evento. Se recomienda a los participantes conectarse al menos 15 minutos antes para permitir la descarga de cualquier software necesario.
韼滊劌 韺岆鞀堩嫲旎姢(NASDAQ: FENC)電� 靸侅梾 雼硠鞚� 鞝勲 鞝滌暯靷, 2025雲� 2攵勱赴 鞛鞁れ爜 氚滍憸毳� 2025雲� 8鞗� 14鞚� 氇╈殧鞚�搿� 鞓堨爼頄堨姷雼堧嫟. 鞁れ爜鞚� 氙戈淡 歃濎嫓 臧滌灔 鞝� 瓿店皽霅橂┌, 鞚挫柎 瓴届榿歆勳潣 旎嵓霟办姢 旖滉臣 鞗轨簮鞀ろ姼臧� 霃欕秬 鞁滉皠 鞓れ爠 8鞁� 30攵�鞐� 歆勴枆霅╇媹雼�.
須岇偓電� 鞛愳偓 鞗轨偓鞚错姼毳� 韱淀暣 霛检澊敫� 鞗轨簮鞀ろ姼毳� 鞝滉车頃橂┌, 鞚措菠韸� 頉� 30鞚缄皠 鞛儩鞚� 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟. 彀戈皜鞛愲姅 頃勳殧頃� 靻岉攧韸胳洦鞏� 雼れ毚搿滊摐毳� 鞙勴暣 斓滌唽 15攵� 鞝勳棎 鞝戩啀頃� 瓴冹潉 甓岇灔頃╇媹雼�.
Fennec Pharmaceuticals (NASDAQ: FENC), une soci茅t茅 pharmaceutique sp茅cialis茅e en phase commerciale, a programm茅 la publication de ses r茅sultats financiers du deuxi猫me trimestre 2025 pour le jeudi 14 ao没t 2025. Les r茅sultats seront diffus茅s avant l'ouverture des march茅s am茅ricains, suivis d'une conf茅rence t茅l茅phonique de la direction et d'un webcast 脿 8h30, heure de l'Est.
L'entreprise proposera un webcast en direct accessible depuis son site web, dont le replay sera disponible pendant trente jours apr猫s l'茅v茅nement. Les participants sont invit茅s 脿 se connecter au moins 15 minutes 脿 l'avance afin de permettre le t茅l茅chargement 茅ventuel de logiciels.
Fennec Pharmaceuticals (NASDAQ: FENC), ein auf dem Markt etabliertes Spezialpharmaunternehmen, hat die Bekanntgabe der Finanzergebnisse f眉r das zweite Quartal 2025 f眉r Donnerstag, den 14. August 2025 terminiert. Die Ergebnisse werden vor 脰ffnung der US-M盲rkte ver枚ffentlicht, gefolgt von einer Management-Konferenzschaltung und einem Webcast um 8:30 Uhr Eastern Time.
Das Unternehmen 眉bertr盲gt den Webcast live 眉ber seine Website; eine Wiederholung steht f眉r drei脽ig Tage nach der Veranstaltung zur Verf眉gung. Teilnehmer sollten sich mindestens 15 Minuten fr眉her einw盲hlen, um eventuelle Software-Downloads durchzuf眉hren.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, August 14, 2025. Management will host a conference call and webcast that day to discuss the Company鈥檚 financial and business results.
Conference Call & Webcast Detail:
Date:聽Thursday, August 14, 2025
Time:聽8:30 a.m. Eastern Time
Webcast Link: 听听
Participant Link:
To access the live webcast link, log onto and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company鈥檚 website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days.
About聽Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to sparing cancer patients further hardship by protecting their ears against the profound threat of cisplatin-induced hearing loss, or ototoxicity. Fennec is focused on the commercialization of PEDMARK庐 to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom (U.K.) approval in October 2023 under the brand name PEDMARQSI.
In聽March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, will commercialize聽PEDMARQSI庐聽in聽Europe,聽U.K., Australia and聽New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany.
PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Further, Fennec has patents providing protection for PEDMARK until 2039 in both the U.S. and internationally.
For more information, please visit and follow on .
For further information, please contact:
Investors:
Robert Andrade
Chief Financial Officer
Fennec Pharmaceuticals Inc.
+1 919-246-5299
Corporate and Media:
Lindsay Rocco
Elixir Health Public Relations
+1 862-596-1304
[email protected]
FAQ
When will Fennec Pharmaceuticals (FENC) release Q2 2025 earnings?
What time is Fennec Pharmaceuticals' Q2 2025 earnings call?
How can investors access Fennec Pharmaceuticals' Q2 2025 earnings call?
Will there be a replay of Fennec Pharmaceuticals' Q2 2025 earnings call?
